Skip to content
Companies

Theradaptive

Implant-binding proteins for bone and tissue repair

Raised to date

$36.2M

of $77.9M offered across 1 Form D filing

Still open
$41.8M
Investors
65
Last filed
Aug 4, 2026

About

Theradaptive is a privately held, clinical-stage biologics company in Frederick, Maryland developing engineered protein therapeutics for spine, orthopedic, dental and soft tissue repair, plus targeted immuno-oncology. Its core AMP2 platform re-engineers naturally occurring proteins so they bind to an implant or graft material and stay where they are placed, delivering a sustained, localized regenerative signal rather than diffusing into surrounding tissue. The company says it has produced hundreds of material-binding variants of recombinant proteins across more than a dozen clinical indications. It was founded by Luis Alvarez, a retired U.S. Army officer and MIT-trained protein engineer who conceived the platform after a combat tour in Iraq.

Its protein variants are engineered to bind to the implant or scaffold material itself, which keeps the therapeutic dose localized and sustained at the repair site. That targeting is aimed squarely at the off-target and safety problems that have limited conventional recombinant BMP-2 bone grafting.

Funding

  • EquityFiled Aug 4, 2026Form D
    $36.2M/ $77.9M

Product

OsteoAdapt SP

Clinical-stage regenerative biologic

An investigational bone graft therapeutic powered by AMP2, a proprietary rhBMP-2 variant engineered for targeted, sustained bone regeneration. It is being developed as an alternative to autologous and allograft bone in lumbar spinal fusion, and is in the pivotal OASIS trial after FDA approval in April 2026 to advance from feasibility to a pivotal study.

  • Powered by AMP2, a proprietary rhBMP-2 variant
  • Binds to the graft material so the dose stays localized and sustained
  • Engineered to minimize off-target effects seen with conventional BMP-2

Built for

Spine and orthopedic surgeons and the hospitals performing lumbar interbody fusion, reached through the regulatory and clinical trial pathway; ultimately patients with symptomatic degenerative lumbosacral spine disease and severe extremity or soft tissue injuries.

People on file